HIV wasting syndrome: Difference between revisions
imported>Robert Badgett No edit summary |
imported>Robert Badgett No edit summary |
||
| Line 7: | Line 7: | ||
| issue = 8 | pages = 2717-2725 | title = Transdermal Testosterone Administration in Women with Acquired Immunodeficiency Syndrome Wasting: A Pilot Study | author = Miller, K. ''et al.'' | http://jcem.endojournals.org/cgi/content/full/83/8/2717|http://jcem.endojournals.org/cgi/content/full/83/8/271}}</ref> A [[systematic review]] by the [[Cochrane Collaboration]] concluded "these results suggest that anabolic steroids may be useful in the treatment of weight loss in HIV infected individuals, due to limitations, treatment recommendations cannot be made."<ref name="pmid16235407">{{cite journal| author=Johns K, Beddall MJ, Corrin RC| title=Anabolic steroids for the treatment of weight loss in HIV-infected individuals. | journal=Cochrane Database Syst Rev | year= 2005 | volume= | issue= 4 | pages= CD005483 | pmid=16235407 | | issue = 8 | pages = 2717-2725 | title = Transdermal Testosterone Administration in Women with Acquired Immunodeficiency Syndrome Wasting: A Pilot Study | author = Miller, K. ''et al.'' | http://jcem.endojournals.org/cgi/content/full/83/8/2717|http://jcem.endojournals.org/cgi/content/full/83/8/271}}</ref> A [[systematic review]] by the [[Cochrane Collaboration]] concluded "these results suggest that anabolic steroids may be useful in the treatment of weight loss in HIV infected individuals, due to limitations, treatment recommendations cannot be made."<ref name="pmid16235407">{{cite journal| author=Johns K, Beddall MJ, Corrin RC| title=Anabolic steroids for the treatment of weight loss in HIV-infected individuals. | journal=Cochrane Database Syst Rev | year= 2005 | volume= | issue= 4 | pages= CD005483 | pmid=16235407 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=16235407 | doi=10.1002/14651858.CD005483 }} </ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=16235407 | doi=10.1002/14651858.CD005483 }} </ref> | ||
Regarding, treatment with [[human growth hormone]], "the evidence supports a role for rhGH in the treatment of patients with HIV-associated wasting."<ref name="pmid18158071">{{cite journal| author=Gelato M, McNurlan M, Freedland E| title=Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment. | journal=Clin Ther | year= 2007 | volume= 29 | issue= 11 | pages= 2269-88 | pmid=18158071 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=18158071 | doi=10.1016/j.clinthera.2007.11.004 }} </ref> | |||
There is considerable interest in the use of [[marijuana]] for the syndrome, and there is substantial use outside formal trials. It has been difficult, however, to get approval for trials. | There is considerable interest in the use of [[marijuana]] for the syndrome, and there is substantial use outside formal trials. It has been difficult, however, to get approval for trials. | ||
Revision as of 10:12, 2 April 2010
According to Medical Subject Headings, HIV wasting syndrome, also called AIDS wasting syndrome, is a complication of Acquired Immune Deficiency Syndrome that is defined as "involuntary weight loss of greater than 10 percent associated with intermittent or constant fever and chronic diarrhea or fatigue for more than 30 days in the absence of a defined cause other than human immunodeficiency virus infection. A constant feature is major muscle wasting with scattered myofiber degeneration. A variety of etiologies, which vary among patients, contributes to this syndrome."[1]
In men, it is associated with hypogonadism and has been treated with androgens and anabolic agents.[2][3] Low androgen levels also have been observed in women, and clinical trials of testosterone patches have shown promise. [4] A systematic review by the Cochrane Collaboration concluded "these results suggest that anabolic steroids may be useful in the treatment of weight loss in HIV infected individuals, due to limitations, treatment recommendations cannot be made."[2]
Regarding, treatment with human growth hormone, "the evidence supports a role for rhGH in the treatment of patients with HIV-associated wasting."[5]
There is considerable interest in the use of marijuana for the syndrome, and there is substantial use outside formal trials. It has been difficult, however, to get approval for trials.
References
- ↑ Anonymous (2024), HIV wasting syndrome (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ 2.0 2.1 Johns K, Beddall MJ, Corrin RC (2005). "Anabolic steroids for the treatment of weight loss in HIV-infected individuals.". Cochrane Database Syst Rev (4): CD005483. DOI:10.1002/14651858.CD005483. PMID 16235407. Research Blogging.
- ↑ Grinspoon, S. et al. (1 July 1998), "Effects of Androgen Administration in Men with the AIDS Wasting Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial", Annals of Internal Medicine 129 (1): 18-26
- ↑ Miller, K. et al. (August 1983), "Transdermal Testosterone Administration in Women with Acquired Immunodeficiency Syndrome Wasting: A Pilot Study", Journal of Clinical Endocrinology & Metabolism 83 (8): 2717-2725
- ↑ Gelato M, McNurlan M, Freedland E (2007). "Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment.". Clin Ther 29 (11): 2269-88. DOI:10.1016/j.clinthera.2007.11.004. PMID 18158071. Research Blogging.